The Corporation is a global multibillion leader in specialty ingredients for the health, beauty, and wellness industries, serving a broad range of markets including cosmetics, pharmaceuticals, nutrition, and industrial applications.

This agreement marks the culmination of a 20-month intense collaboration with Eevia, which began with the signing of a non-disclosure agreement in October 2023 and continued through 2024, see press release on June 27, 2024.

The preparations include a feasibility study, safety and regulatory assessments, and industrial-scale production trials of Feno-Chaga™ Organic. These efforts have confirmed the product's safety and commercial readiness. Feno-Chaga™ Organic is a high-strength, pure and excipient free extract from wild-harvested Chaga mushroom (Inonotus Obliquus), also named the King of Mushrooms, that grows on birch trees in the Arctic Forest of Finland. The extract contains high concentrations of polyphenols and polysaccharides, especially beta-glucans, and is known for its many health benefits.

The new global supply agreement is for a five-year period with the possibility for extensions, and outlines minimum sales volumes, quality assurance standards, and commercial terms. The Supply Agreement will allow the Eevia product to be marketed actively for a significant global market, although under a new tradename. The Partner will lead marketing, clinical research, and global sales, leveraging its strong distribution network to drive demand and market penetration.

"By outsourcing sales, marketing, and clinical studies, Eevia can focus on manufacturing and supply chain operations. Our Partner's investment in clinical substantiation and commercialization allows Eevia to scale this product without incurring major development costs, fuelling our revenue growth while enabling us to focus our scarce resources on other ingredients in our portfolio." says Erik Eide, Commercial Director of Eevia Health."

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was initially submitted for publication through the contact person's agency on May 23, 2025, at 12:40 EST.